# UroGen Pharma (stock symbol: URGN) Logo in transparent PNG and SVG formats

## UroGen Pharma Logo large

### UroGen Pharma Logo large Download PNG (46.44 KB)

![UroGen Pharma Logo large Download PNG (46.44 KB)](/img/orig/URGN_BIG-88501d47.png)

### UroGen Pharma Logo large Download SVG (6.59 KB)

![UroGen Pharma Logo large Download SVG (6.59 KB)](/img/orig/URGN_BIG-f7767fde.svg)

## UroGen Pharma Logo icon format

### UroGen Pharma Logo icon format Download PNG (80.86 KB)

![UroGen Pharma Logo icon format Download PNG (80.86 KB)](/img/orig/URGN-ef45d640.png)

### UroGen Pharma Logo icon format Download SVG (1.87 KB)

![UroGen Pharma Logo icon format Download SVG (1.87 KB)](/img/orig/URGN-04dcbfb0.svg)

## UroGen Pharma Logo large for dark backgrounds

### UroGen Pharma Logo large for dark backgrounds Download PNG (28.97 KB)

![UroGen Pharma Logo large for dark backgrounds Download PNG (28.97 KB)](/img/orig/URGN_BIG.D-fb24b41d.png)

### UroGen Pharma Logo large for dark backgrounds Download SVG (6.59 KB)

![UroGen Pharma Logo large for dark backgrounds Download SVG (6.59 KB)](/img/orig/URGN_BIG.D-23faa2b4.svg)

## UroGen Pharma Logo icon format for dark backgrounds

### UroGen Pharma Logo icon format for dark backgrounds Download PNG (46.99 KB)

![UroGen Pharma Logo icon format for dark backgrounds Download PNG (46.99 KB)](/img/orig/URGN.D-995dcf12.png)

### UroGen Pharma Logo icon format for dark backgrounds Download SVG (1.86 KB)

![UroGen Pharma Logo icon format for dark backgrounds Download SVG (1.86 KB)](/img/orig/URGN.D-02a4440c.svg)

## About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

1. Website domain: urogen.com
2. Employees: 195
3. Marketcap: $0.27 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
